- Conditions
- Atherosclerosis
- Interventions
- SB-480848 (darapladib)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- King of Prussia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atherosclerosis
- Interventions
- Darapladib (SB480848)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 20 Years to 64 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Atherosclerosis
- Interventions
- SB 480848, tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 4
- States / cities
- Cypress, California • Normal, Illinois • North Dartmouth, Massachusetts + 1 more
- Conditions
- Atherosclerosis
- Interventions
- Darapladib, Diltiazem
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Atherosclerosis
- Interventions
- Darapladib, Midazolam
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Endothelial Dysfunction
- Interventions
- darapladib, placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Coronary Syndrome
- Interventions
- Darapladib 160 mg, Placebo, Standard Therapy
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,026 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 290
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
- Conditions
- Atherosclerosis
- Interventions
- darapladib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Atherosclerosis
- Interventions
- Rosuvastatin 10 mg, Darapladib 160 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 20 Years to 64 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Atherosclerosis
- Interventions
- SB-480848, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 969 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 24 more
- Conditions
- Atherosclerosis
- Interventions
- darapladib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Atherosclerosis
- Interventions
- Darapladib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Atherosclerosis
- Interventions
- Darapladib, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
- Conditions
- Atherosclerosis
- Interventions
- Darapladib 160 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Minneapolis, Minnesota